Zelluna reports Q2 loss as cancer therapy trial advances
Zelluna, a Norwegian cell therapy firm, announced a Q2 loss of NOK 19.7 million amid progress in its cancer treatment trial. The company initiated the first patient into Phase 1 trials of ZIMA-101 during the quarter. Preliminary safety data from the trial showed positive outcomes, stated the company's quarterly report. Zelluna added The Royal Marsden as an additional clinical site for the ZIMA-101 trial, with patient recruitment currently active at two locations.
The firm raised NOK 58.2 million through a private placement and retail offering in the second quarter, and secured a NOK 16 million grant to aid its clinical trial and operations. Operating expenses for the quarter amounted to NOK 19.90 million. Zelluna stated its remaining cash reserves will sustain operations until the third quarter of 2027.
The company is focusing on enhancing its manufacturing capabilities to support the development of its TCR-NK platform.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
